Pharmaceutical giant GlaxoSmithKline (GSK) is to make 190 employees redundant at its site in Ulverston.

The company announced in July 2017 that it would no longer build a £350m biopharm facility, which had been planned for the area.

It also said it would carry out a strategic review of its operations, which has now concluded with the announcement that almost 200 jobs will be lost.

The company says the tablet side of its sterile manufacturing business is cost effective, but its injectables are not, so it is closing that side of its business in Ulverston.

There will be a phased reduction of jobs from now until the end of 2020, and the first jobs will go in June 2019.

The site is one of the biggest employers in Ulverston, with 345 staff.